Unlike previous reports of the reversible EGFR TKIs, erlotinib and gefitinib, the combined analyses of LUX-Lung 3 and LUX-Lung 6 studies demonstrated that first-line irreversible TKI afatinib provided a longer OS for common EGFR mutated NSCLC patients compared with chemotherapy [24]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.